Dynorphin A (Human, 1-13)

<strong>Dynorphin A (Human, 1-13)</strong> <strong>Catalog number:</strong> MDP0443 <strong>CAS Number: </strong>35364-70-6 <strong>Sequence: </strong>Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys <strong>Amount:</strong> 500 ug <strong>Molecular Weight:</strong> 1604 g/mol <strong>Supplied as:</strong> Powder <strong>Applications:</strong> molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>WARNING:</strong> For in vitro Research Use Only. NOT for use on humans or animals. <strong>Grade:</strong> Biotechnology grade. All products are highly pure. <strong>References:</strong> 1: Müller S, Hochhaus G. Metabolism of dynorphin A 1-13 in human blood and plasma Pharm Res. 1995 Aug;12(8):1165-70. 2: Brugos B, Hochhaus G. Metabolism of dynorphin A(1-13) Pharmazie. 2004 May;59(5):339-43. 3: Gambús PL, Schnider TW, Minto CF, Youngs EJ, Billard V, Brose WG, Hochhaus G, Shafer SL. Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers Clin Pharmacol Ther. 1998 Jul;64(1):27-38. 4: Greenwald MK, Stitzer ML, Haberny KA. Human pharmacology of the opioid neuropeptide dynorphin A(1-13) J Pharmacol Exp Ther. 1997 Jun;281(3):1154-63. 5: Specker S, Wananukul W, Hatsukami D, Nolin K, Hooke L, Kreek MJ, Pentel PR. Effects of dynorphin A(1-13) on opiate withdrawal in humans Psychopharmacology (Berl). 1998 Jun;137(4):326-32. 6: Chou JZ, Chait BT, Wang R, Kreek MJ. Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo Peptides. 1996;17(6):983-90. 7: Dumont M, Lemaire S. Interactions of dynorphin A-(1-13) and nociceptin with cardiac D2 binding sites: inhibition of ischemia-evoked release of noradrenaline from synaptosomal-mitochondrial fractions J Mol Cell Cardiol. 2000 Aug;32(8):1567-74. 8: King AC, Ho A, Schluger J, Borg L, Kreek MJ. Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects Drug Alcohol Depend. 1999 Mar 1;54(1):87-90. 9: Hiramatsu M, Mori H, Murasawa H, Kameyama T. Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats Br J Pharmacol. 1996 May;118(2):255-60. <a href="https://pubmed.ncbi.nlm.nih.gov/7667358">10: Pentel PR, Wananukul W, Hooke LP, Jones CR, Hatsukami D, Anderson WR, Lee NM. Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):387-90. </a> <br><strong>Products Related to Dynorphin A (Human, 1-13) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>